CDSCO Regulatory Alerts

CDSCO Suspends HCG Bangalore Institute of Oncology, Bengaluru’s Ethics Committee Following Compliance Failures & debarred two Principal Investigators

Regulatory Crackdown: CDSCO Suspends HCG Bengaluru Ethics Committee and Debars Two Top Investigators Following Critical Trial Lapses

In a major regulatory enforcement action signaling a zero-tolerance policy for clinical trial non-compliance, the Central Drugs Standard Control Organization (CDSCO) has issued dual penal orders targeted at the HCG Bangalore Institute of Oncology.

Signed by the Drugs Controller General of India (DCGI) and Central Licensing Authority (CLA), Dr. Rajeev Singh Raghuvanshi, the coordinated regulatory action—dated June 12, 2026—officially suspends the registration of the HCG Central Ethics Committee for 24 months and debars two of its prominent Principal Investigators (PIs) from conducting new clinical studies.

The sweeping penalties stem from a comprehensive, risk-based joint inspection conducted by officials from the CDSCO Headquarters, the CDSCO Zonal Office in Bengaluru, the State Licensing Authority (SLA) of Karnataka, and independent subject matter experts. The investigation originally stemmed from whistleblower complaints and subsequent media exposes detailing severe, systemic breaches of the New Drugs and Clinical Trials Rules (NDCTR), 2019 and Indian Good Clinical Practice (GCP) Guidelines.

Part 1: The Lapses and Suspension of the Ethics Committee (EC)

The foundational pillar of institutional human trial oversight at HCG’s flagship Sampangiram Nagar (Kalinga Rao Road) unit has been temporarily dismantled. For a period of 24 months, the HCG Central Ethics Committee is barred from approving or reviewing any new clinical trials or Bioavailability/Bioequivalence (BA/BE) studies.

The CDSCO’s inspection uncovered chilling systemic operational defects within the committee:

• Suppression and Delay of Participant Deaths: The committee failed to report nine Serious Adverse Events (SAEs)—including three participant deaths—to the Central Licensing Authority within the legally mandated timelines. Other reported casualties were submitted with egregious delays far exceeding the 30-day window.
• Causality Assessment Failures: In one catastrophic instance, a trial participant suffered from severe progressive liver disease alongside their primary diagnosis. The patient was discharged without receiving continuous, free medical management or documented laboratory follow-ups (such as repeated Liver Function Tests). The patient passed away the following day. Despite this trajectory, the Ethics Committee accepted a medical casualty assessment stating the death was entirely “unrelated” to the trial drug, completely failing to perform objective, rigorous causality verification before informing regulators 10 months later.
• Severe Administrative Deficiencies: Regulators found that the EC could not provide formal organizational documentation, rules, or defined responsibilities for its own SAE review sub-committee. Furthermore, official meeting minutes from multiple sessions lacked the required signature of the Chairperson, and several meetings proceeded entirely without a legally valid quorum.

Part 2: Escalated Action — Debarment of the Principal Investigators

Moving beyond institutional penalties, the CLA determined that the gravity of the violations warranted personal accountability. Because the primary layer of human subject protection relies on the clinical investigators themselves, two senior doctors heading the trials have been slapped with direct debarment orders under Rule 30(1)(iv) of the NDCTR, 2019.

1. Dr. Satheesh C.T. — Debarred for 24 Months

Regulators observed a massive concentration of trial management power paired with an extreme breakdown of personal oversight. Dr. Satheesh was found to be acting as the designated Principal Investigator for 42 out of 99 clinical trials running at the site.

The CDSCO held him personally liable for the site’s most critical medical failures, including:

• Failing to report patient deaths and serious adverse events directly to the CLA.
• Neglecting to secure and document adequate free medical management and safety follow-ups for deteriorating patients under his care.
• Allowing long lists of protocol deviations to go entirely unrecorded or unreported for months at a time.

Consequently, he is completely disqualified from undertaking any new clinical trials or BA/BE studies for two years.

2. Dr. Govind Babu — Debarred for 6 Months

Dr. Govind Babu’s debarment addresses a fundamental violation of bioethics: a severe, unmanaged conflict of interest.

During an examination of the Ethics Committee’s meeting minutes from September 25, 2024, regulators discovered that Dr. Babu signed an official document declaring he had “no conflict of interest” regarding a study under review. In reality, Dr. Babu was simultaneously serving as a voting member of the Ethics Committee and the Principal Investigator (PI) of the very trial being evaluated. Furthermore, it was discovered that a mandatory Conflict of Interest declaration was entirely missing for another protocol under his supervision. Dr. Babu subsequently admitted to regulators that the documentation was “inadvertently not obtained.”

Summary of the CDSCO Enforcement Orders

Sanctioned Entity	Penalty Type	Duration	Mandated Directives / Next Steps
HCG Central Ethics Committee	Registration Suspension	24 Months	Must submit a comprehensive Corrective and Preventive Action (CAPA) plan; barred from onboarding any new studies.
Dr. Satheesh C.T. (PI)	Personal Debarment	24 Months	Barred from starting new trials; must actively manage existing trials with strict monthly safety reporting.
Dr. Govind Babu (PI)	Personal Debarment	6 Months	Barred from starting new trials; penalized for dual-role conflict of interest violations.

The Path Forward for Patient Safety

To ensure that the hundreds of patients currently enrolled in ongoing trials at HCG are not left stranded or compromised by these administrative suspensions, the CDSCO has woven strict safety-net clauses into the orders.

Both the suspended Ethics Committee and the debarred Principal Investigators have been strictly commanded to maintain active, continuous supervision over all active, ongoing studies. They are required to submit exhaustive, mandatory monthly status reports documenting the safety, well-being, and medical management of current trial participants directly to the CDSCO Headquarters and its Zonal Office in Bengaluru.

Industry Takeaway

This multi-layered enforcement action marks a pivotal moment for clinical research in India. By simultaneously going after the institutional oversight body (the Ethics Committee) and the medical professionals on the ground (the Principal Investigators), the CDSCO has sent an unequivocal message to hospital networks across the nation: patient safety timelines, conflict-of-interest declarations, and transparent casualty reporting are non-negotiable legal mandates, not administrative guidelines.

Regulatory Notifications Issued by CDSCO :

List of Suspended Ethics Committee by CLA
https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTQzOTI=

List of Debarment of Principal Investigators by CLA https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTQzOTM=